Dose: 10 mg
Single Dose: 10 (10)
Frequency: 6 hourly
Route: PO
Instructions: Should be taken 15 min before meals and bed time.

. It is of Synthetic origin and belongs to Benzamide. . The Molecular Weight of Cisapride is 484.00. Its pKa is 9100.

Cisapride is contraindicated in conditions like Intestinal obstruction.

The severe or irreversible adverse effects of Cisapride, which give rise to further complications include Cardiac arrhythmias, Asthma.Cisapride produces potentially life-threatening effects which include Torsades de pointes. which are responsible for the discontinuation of Cisapride therapy.The signs and symptoms that are produced after the acute overdosage of Cisapride include Diarrhea, Abdominal cramps, Ventricular arrhythmias, Q.T interval prolongation.The symptomatic adverse reactions produced by Cisapride are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Abdominal cramps, Borborygmi.

Cisapride is primarily indicated in conditions like Delayed gastric emptying, Dyspepsia, Gastro-esophageal reflux disease, GI motality disorder.

Cisapride is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmiodarone (HCl)Amitriptyline (HCl)Cisapride can cause ventricular arrhythmia due to prolong QT interval when given with Amitriptyline.MajorThis combination is contraindicated.AstemizoleCilostazoleCimetidine (HCl)Cimetidine increases the plasma concentration of cisapride by inhibiting its metabolic clearence.Increased level of cisapide results in prolongation of QT interval on ECG, ventricular arrythmia, cardiac arrest and sudden death.MajorCoadministration should be avoided. Famotidine, nizatidine, ranitidine considered as safer alternatives of cimetidine.ClarithromycinClarithromycin increases the plasma concentration of cisapride by inhibiting its metabolism result in prolongation of QT interval on ECG, ventricular arrythmia, cardiac arrest and death.MajorThis combination is considered contraindicated.Cyclosporin ACyclosporin increases the plasma concentration of cisapride by inhibiting its metabolic clearence.Increased level of cisapide results in prolongation of QT interval on ECG, ventricular arrythmia, cardiac arrest and sudden death.MajorCoadministration should be avoided.ErythromycinErythromycinFluconazoleFluconazole by inhibiting CYP450 3A4 increases plasma concentration of cisapride thus prolong QT interval leads to ventricular arrhythmias,cardiac arrest and sudden death may also occur.MajorCoadministration of both drugs sre contraindicated.Flurazepam (HCl)Halofantrine (HCl)Indinavir (Sulphate)Indinavir increases the plasma concentration of cisapride by inhibiting its metabolic clearence. Increased level of cisapide results in prolongation of QT interval on ECG, ventricular arrythmia, cardiac arrest and sudden death.MajorCoadministration should be avoided.ItraconazoleItraconazoleKetoconazoleKetoconazole increases the plasma concentration of cisapride by inhibiting its metabolic clearence resulting prolongation of QT interval, ventricular arrythmia, cardiac arrest and sudden death.MajorThis combination is considered contraindicated.Mibefradil (Di HCl)Miconazole (Nitrate)MoxifloxacinNelfinavirNevirapineOxycodoneQuinineQuinupristinThe manufacturer states that quinupristin may increase cisapride concentrations and cause QTc prolongation.Avoid concurrent use with cisapride.RitonavirRitonavir increases the plasma concentration of cisapride by inhibiting its metabolic clearence. Increased level of cisapide results in prolongation of QT interval on ECG, ventricular arrythmia, cardiac arrest and sudden death.MajorCoadministration should be avoided.TelithromycinThe use of Teicoplanin is contraindicated with cisapride.TerfenadineTicagrelorcisapride is CYP3A54 substrate, its exposure may increase by ticagrelor which is CYP3A4 enzyme inhibitorco administration is not recommendedVandetanibCisapride, vandetanib, arsenic and erythromycin all increase QT prolongation.Combination is not recommended.VORICONAZOLEVoriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism.Concomitant therapy is contraindicated. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Susp Store in a well closed container, Below 40°C. Protect from Sunlight and Heat.

Cisapride should be used with caution in patients with any pre-existing intestinal disorders, bleeding ulcers, asthma, kidney or heart problems or any allergy. This medication should be used only if clearly needed during pregnancy or lactation.